Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5860 | 1496 | 38.9 | 76% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CD26 | Author keyword | 188 | 67% | 11% | 170 |
2 | DIPEPTIDYL PEPTIDASE IV | Author keyword | 92 | 38% | 13% | 193 |
3 | SEPRASE | Author keyword | 86 | 96% | 2% | 26 |
4 | FIBROBLAST ACTIVATION PROTEIN | Author keyword | 68 | 79% | 3% | 44 |
5 | DIPEPTIDYL PEPTIDASE | Author keyword | 52 | 59% | 4% | 58 |
6 | FIBROBLAST ACTIVATION PROTEIN ALPHA | Author keyword | 41 | 90% | 1% | 18 |
7 | DPP9 | Author keyword | 21 | 75% | 1% | 15 |
8 | IMMUNOPHARM | Address | 21 | 90% | 1% | 9 |
9 | DPP8 | Author keyword | 15 | 67% | 1% | 14 |
10 | THER Y DEV INNOVAT IMMUNE DISORDERS CAN | Address | 15 | 71% | 1% | 12 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CD26 | 188 | 67% | 11% | 170 | Search CD26 | Search CD26 |
2 | DIPEPTIDYL PEPTIDASE IV | 92 | 38% | 13% | 193 | Search DIPEPTIDYL+PEPTIDASE+IV | Search DIPEPTIDYL+PEPTIDASE+IV |
3 | SEPRASE | 86 | 96% | 2% | 26 | Search SEPRASE | Search SEPRASE |
4 | FIBROBLAST ACTIVATION PROTEIN | 68 | 79% | 3% | 44 | Search FIBROBLAST+ACTIVATION+PROTEIN | Search FIBROBLAST+ACTIVATION+PROTEIN |
5 | DIPEPTIDYL PEPTIDASE | 52 | 59% | 4% | 58 | Search DIPEPTIDYL+PEPTIDASE | Search DIPEPTIDYL+PEPTIDASE |
6 | FIBROBLAST ACTIVATION PROTEIN ALPHA | 41 | 90% | 1% | 18 | Search FIBROBLAST+ACTIVATION+PROTEIN+ALPHA | Search FIBROBLAST+ACTIVATION+PROTEIN+ALPHA |
7 | DPP9 | 21 | 75% | 1% | 15 | Search DPP9 | Search DPP9 |
8 | DPP8 | 15 | 67% | 1% | 14 | Search DPP8 | Search DPP8 |
9 | CD26 DPPIV | 15 | 73% | 1% | 11 | Search CD26+DPPIV | Search CD26+DPPIV |
10 | DPPIV | 13 | 46% | 1% | 21 | Search DPPIV | Search DPPIV |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CD26 | 222 | 61% | 16% | 234 |
2 | EPITHELIAL CANCERS | 96 | 68% | 6% | 84 |
3 | DIPEPTIDYL PEPTIDASE IV | 80 | 24% | 20% | 296 |
4 | AMINOPEPTIDASE IV | 77 | 73% | 4% | 59 |
5 | FIBROBLAST ACTIVATION PROTEIN | 55 | 44% | 6% | 96 |
6 | INTEGRAL MEMBRANE PROTEASE | 50 | 86% | 2% | 25 |
7 | MEMBRANE BOUND PROTEASE | 49 | 94% | 1% | 17 |
8 | ADENOSINE DEAMINASE BINDING | 46 | 82% | 2% | 27 |
9 | PEPTIDASE IV | 44 | 46% | 5% | 70 |
10 | SEPRASE | 43 | 79% | 2% | 27 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Dipeptidyi-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV | 2003 | 346 | 463 | 50% |
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? | 2009 | 74 | 66 | 68% |
Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy | 2012 | 32 | 71 | 63% |
Fibroblast activation protein A potential therapeutic target in cancer | 2012 | 22 | 63 | 84% |
The role of CD26/dipeptidyl peptidase IV in cancer | 2008 | 65 | 103 | 83% |
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function | 2008 | 73 | 67 | 73% |
CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes | 2001 | 183 | 190 | 77% |
CD26, let it cut or cut it down | 1999 | 285 | 74 | 68% |
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders | 2005 | 149 | 132 | 65% |
The multifunctional or moonlighting protein CD26/DPPIV | 2003 | 143 | 218 | 65% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IMMUNOPHARM | 21 | 90% | 0.6% | 9 |
2 | THER Y DEV INNOVAT IMMUNE DISORDERS CAN | 15 | 71% | 0.8% | 12 |
3 | JOINT CANC CELL BIOL | 13 | 67% | 0.8% | 12 |
4 | CLIN IMMUNOLMINATO KU | 5 | 33% | 0.9% | 13 |
5 | UNIV CLIN DERMATOL VENEREOL | 5 | 55% | 0.4% | 6 |
6 | RHEUMATOL ALLERGYMINATO KU | 3 | 57% | 0.3% | 4 |
7 | AW MORROW GASTROENTEROL LIVER | 3 | 12% | 1.7% | 25 |
8 | DUMONT UCLA TRANSPLANTAT | 3 | 60% | 0.2% | 3 |
9 | ERS 572 CNRS | 3 | 60% | 0.2% | 3 |
10 | MED CHEM UAMC | 3 | 60% | 0.2% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000215753 | DPP 4 INHIBITOR//SITAGLIPTIN//VILDAGLIPTIN |
2 | 0.0000157523 | PROLYL OLIGOPEPTIDASE//PROLYL ENDOPEPTIDASE//OLIGOPEPTIDASE B |
3 | 0.0000105098 | CD13//AMINOPEPTIDASE N//UBENIMEX |
4 | 0.0000082681 | ZITTER RAT//ATTRACTIN//SPONTANEOUSLY EPILEPTIC RAT SER |
5 | 0.0000082592 | DIPEPTIDYL PEPTIDASE III//GOAT BRAIN//PEPTIDASE FAMILY M49 |
6 | 0.0000072315 | PROLYLCARBOXYPEPTIDASE//PRCP//ANGIOTENSINASE C |
7 | 0.0000068721 | PROLIDASE//PROLIDASE DEFICIENCY//PROLIDASE ACTIVITY |
8 | 0.0000050545 | JEFFERSON STEM CELL BIOL REGENERAT MED//CANCER ASSOCIATED FIBROBLASTS//CANCER ASSOCIATED FIBROBLAST |
9 | 0.0000046785 | PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY//ADENOSINE DEAMINASE//CECR1 |
10 | 0.0000044945 | BETA CASOMORPHINS//BETA CASOMORPHIN//HUMAN BETA CASEIN |